CN1653050B - 阿片和阿片样化合物及其用途 - Google Patents

阿片和阿片样化合物及其用途 Download PDF

Info

Publication number
CN1653050B
CN1653050B CN038112396A CN03811239A CN1653050B CN 1653050 B CN1653050 B CN 1653050B CN 038112396 A CN038112396 A CN 038112396A CN 03811239 A CN03811239 A CN 03811239A CN 1653050 B CN1653050 B CN 1653050B
Authority
CN
China
Prior art keywords
compound
purposes according
purposes
compounds
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN038112396A
Other languages
English (en)
Chinese (zh)
Other versions
CN1653050A (zh
Inventor
范进财
颜茂雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyi Biomedicine Shanghai Co ltd
Original Assignee
Jenken Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenken Biosciences Inc filed Critical Jenken Biosciences Inc
Priority to CN201310094981.6A priority Critical patent/CN103405431B/zh
Publication of CN1653050A publication Critical patent/CN1653050A/zh
Application granted granted Critical
Publication of CN1653050B publication Critical patent/CN1653050B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN038112396A 2002-05-17 2003-05-16 阿片和阿片样化合物及其用途 Expired - Lifetime CN1653050B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310094981.6A CN103405431B (zh) 2002-05-17 2003-05-16 阿片和阿片样化合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38084102P 2002-05-17 2002-05-17
US60/380,841 2002-05-17
PCT/US2003/015461 WO2003097608A2 (en) 2002-05-17 2003-05-16 Opioid and opioid-like compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310094981.6A Division CN103405431B (zh) 2002-05-17 2003-05-16 阿片和阿片样化合物及其用途

Publications (2)

Publication Number Publication Date
CN1653050A CN1653050A (zh) 2005-08-10
CN1653050B true CN1653050B (zh) 2013-04-24

Family

ID=29550023

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310094981.6A Expired - Lifetime CN103405431B (zh) 2002-05-17 2003-05-16 阿片和阿片样化合物及其用途
CN038112396A Expired - Lifetime CN1653050B (zh) 2002-05-17 2003-05-16 阿片和阿片样化合物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310094981.6A Expired - Lifetime CN103405431B (zh) 2002-05-17 2003-05-16 阿片和阿片样化合物及其用途

Country Status (9)

Country Link
EP (2) EP1506174B1 (OSRAM)
JP (3) JP5438250B2 (OSRAM)
CN (2) CN103405431B (OSRAM)
AU (2) AU2003234621A1 (OSRAM)
CA (1) CA2486157C (OSRAM)
HK (1) HK1220452A1 (OSRAM)
MX (1) MXPA04011327A (OSRAM)
TW (1) TWI275591B (OSRAM)
WO (1) WO2003097608A2 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521914Y2 (ja) 1988-12-23 1997-01-08 エヌティエヌ株式会社 大型転がり軸受
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20040204862A1 (en) 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
AU2005244852B2 (en) * 2004-05-12 2011-09-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
AU2005244401B2 (en) 2004-05-14 2009-01-22 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PT2357183E (pt) 2007-05-01 2015-09-28 Concert Pharmaceuticals Inc Compostos de morfinano
US8329897B2 (en) 2007-07-26 2012-12-11 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2704628C (en) 2007-11-16 2016-11-29 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
PL2596784T3 (pl) * 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8569292B2 (en) 2008-05-01 2013-10-29 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
PL2300461T3 (pl) 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
CL2009001151A1 (es) 2008-05-13 2010-08-13 Boehringer Ingelheim Int Compuestos derivados de acidos carbociclicos aliciclicos de benzomorfanos, procedimiento de preparacion, composicion farmaceutica, utiles para tratar enfermedades influenciadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa, como trastornos metabolicos.
JP5379160B2 (ja) 2008-07-25 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010033801A1 (en) 2008-09-19 2010-03-25 Concert Pharmaceuticals Inc. Morphinan compounds
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
TWI531571B (zh) 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
AU2011250485B2 (en) * 2010-05-03 2016-07-07 Tsh Biopharm Corporation, Limited Pharmaceutical composition and method for treating hypertension
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
ES2604931T3 (es) * 2010-12-23 2017-03-10 Phoenix Pharmalabs, Inc. Nuevos morfinanos útiles como analgésicos
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
CN102731399B (zh) * 2012-07-06 2013-11-06 启东东岳药业有限公司 高纯度3-甲氧基-9α,13α,14α吗啡喃盐酸盐的制备方法
CN103254131A (zh) * 2013-04-23 2013-08-21 苏州谷力生物科技有限公司 一种右美沙芬原料药的精制工艺
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
JP6248711B2 (ja) 2014-03-06 2017-12-20 株式会社デンソー 回転電機の固定子
US9757372B2 (en) 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2717677C1 (ru) 2016-04-22 2020-03-25 Тайваньж Фармасьютикалс Со., Лтд. Налмефен, налтрексон или их производные для применения в лечении (не)алкогольного стеатогепатита или неалкогольной жировой болезни печени
CN110290792A (zh) * 2017-01-05 2019-09-27 景凯生物科技股份有限公司 吗啡喃衍生物和其用于治疗自体免疫、发炎或感染相关的障碍的组合物
CN107157998A (zh) * 2017-05-26 2017-09-15 张灏 右美沙芬的新用途
WO2020172248A1 (en) * 2019-02-19 2020-08-27 Robert Barsotti Solutions and methods for organ preservation
CN119977886B (zh) * 2025-02-13 2025-08-22 安徽益普克医药科技发展有限公司 一种葡萄糖酸喷他佐辛苯甲酸酯及其制备方法与用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267182A (en) * 1979-01-16 1981-05-12 The United States Of America As Represented By The Secretary Of The Army Narcotic antagonists in the therapy of shock
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
WO2002016367A1 (en) * 2000-08-25 2002-02-28 Glaxo Wellcome Australia Ltd Chemical methods
WO2002036573A2 (en) * 2000-10-31 2002-05-10 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) 1966-09-27 Chjcoo-
NL127995C (OSRAM) 1963-12-20 Geigy Ag J R
GB1038732A (en) 1963-12-31 1966-08-10 Hoffmann La Roche Morphinan derivatives and a process for the manufacture thereof
IE34235B1 (en) 1969-06-04 1975-03-19 Acf Chemiefarma Nv 6,7-benzomorphans and their preparation
CA919668A (en) 1970-06-20 1973-01-23 Murakami Masuo Morphinan derivatives
BE788478A (fr) 1971-09-08 1973-03-06 Bristol Myers Co Procede de preparation de composes analgesiques
DE2238839A1 (de) * 1972-08-07 1974-02-14 Boehringer Sohn Ingelheim Neue morphinon-derivate, deren saeureadditionssalze, verfahren zu ihrer herstellung sowie ihre verwendung zur herstellung von arzneimitteln
DE2259979A1 (de) 1972-12-07 1974-06-12 Bayer Ag Benzomorphan-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS514175A (en) * 1974-07-01 1976-01-14 Yamanouchi Pharma Co Ltd Morufuinanjudotaino goseiho
GB1513961A (en) 1975-02-25 1978-06-14 Acf Chemiefarma Nv 6,7-benzomorphans method for their preparation and intermediates
US4029798A (en) 1975-06-02 1977-06-14 Sumitomo Chemical Company, Limited Analgetic composition
GB1575009A (en) 1976-06-21 1980-09-17 Acf Chemiefarma Nv 6,7-benzomorphan derivatives
US4161597A (en) * 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
CA1093070A (en) 1978-02-10 1981-01-06 Michael P. Kotick 8.beta.-ALKYL-SUBSTITUTED MORPHINAN-6-ONE COMPOUNDS
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4228285A (en) 1979-02-28 1980-10-14 Bristol-Myers Company 14-Hydroxy-6-oxamorphinans and 14-hydroxy-6-oxaisomorphinans
US4390699A (en) 1981-07-16 1983-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 6-Keto-morphinans belonging to the 14-hydroxy-series
US4388463A (en) 1981-07-16 1983-06-14 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services 6-Keto-morphinan analgesics
IN163125B (OSRAM) 1985-01-08 1988-08-13 Alkaloida Vegyeszeti Gyar
HU196376B (en) 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4912114A (en) 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
FR2636330B1 (fr) 1988-09-13 1990-11-30 Sanofi Sa Procede de preparation de derives de morphinane
GB9103302D0 (en) * 1991-02-16 1991-04-03 Smithkline Beecham Plc Pharmaceutical formulations
US5556857A (en) * 1991-05-08 1996-09-17 Otsuka Pharmaceutical Co., Ltd. Disturbance-of-consciousness improving agent
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
DE4121821A1 (de) 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
US5219347A (en) 1991-12-24 1993-06-15 Laser Engineering, Inc. Decoupled dual-beam control system
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
US6271239B1 (en) 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
TW264473B (OSRAM) * 1993-01-06 1995-12-01 Hoffmann La Roche
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
NZ268969A (en) * 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
CZ281174B6 (cs) 1993-08-13 1996-07-17 Galena, A.S. Způsob přípravy 3,14ß-dihydroxy-17-normorfinanu
BR9610480A (pt) * 1995-09-19 1999-03-16 Solomon Begelfor Margolin Inibição do fator alfa de necrose tumoral
DE19602959A1 (de) 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
GB9616253D0 (en) * 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
US5912347A (en) 1996-09-30 1999-06-15 Mallinckrodt Inc. Process for preparing a morphinan derivative
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
JPH1160483A (ja) * 1997-08-25 1999-03-02 Akira Kanematsu Ｔｎｆ産生阻害剤
JPH1160484A (ja) * 1997-08-25 1999-03-02 Akira Kanematsu Ｔｎｆ産生阻害剤
US6166211A (en) * 1999-03-19 2000-12-26 Endo Pharmaceuticals, Inc. Sequential benzylic oxidations of the naloxone ring system
JP2001058957A (ja) * 1999-08-20 2001-03-06 Toray Ind Inc 癌転移抑制剤
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267182A (en) * 1979-01-16 1981-05-12 The United States Of America As Represented By The Secretary Of The Army Narcotic antagonists in the therapy of shock
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
WO2002016367A1 (en) * 2000-08-25 2002-02-28 Glaxo Wellcome Australia Ltd Chemical methods
WO2002036573A2 (en) * 2000-10-31 2002-05-10 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents

Also Published As

Publication number Publication date
EP2987788A1 (en) 2016-02-24
TWI275591B (en) 2007-03-11
MXPA04011327A (es) 2005-08-15
EP1506174A2 (en) 2005-02-16
WO2003097608A3 (en) 2004-03-18
EP1506174B1 (en) 2015-09-30
JP6165592B2 (ja) 2017-07-19
JP2015155449A (ja) 2015-08-27
CN1653050A (zh) 2005-08-10
HK1220452A1 (en) 2017-06-09
JP2005530798A (ja) 2005-10-13
AU2003234621A1 (en) 2003-12-02
CA2486157C (en) 2013-04-16
JP2014043452A (ja) 2014-03-13
CN103405431B (zh) 2016-04-13
CA2486157A1 (en) 2003-11-27
TW200427690A (en) 2004-12-16
AU2010212517A1 (en) 2010-09-16
WO2003097608A2 (en) 2003-11-27
JP5438250B2 (ja) 2014-03-12
CN103405431A (zh) 2013-11-27
HK1192711A1 (zh) 2014-08-29
JP6193298B2 (ja) 2017-09-06

Similar Documents

Publication Publication Date Title
CN1653050B (zh) 阿片和阿片样化合物及其用途
US8404706B2 (en) Opioid and opioid-like compounds and uses thereof
US8362007B1 (en) Substituted noribogaine
JP4532109B2 (ja) 新規オリパビン誘導体および医薬としてのその使用
JPH0648944A (ja) 経口投与のための鎮痛剤
JP2002501923A (ja) 治療用化合物
US9776971B2 (en) Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) Opioid and opioid-like compounds and uses thereof
JPH1087667A (ja) モルフィナンヒドロキサム酸化合物
JPWO1997011948A1 (ja) インドール誘導体およびその医薬用途
TWI430992B (zh) 類鴉片及類似之類鴉片化合物及其用途（二）
HK1192711B (en) Opioid and opioid-like compounds and uses thereof
JPWO2001014382A1 (ja) モルヒナン４級アンモニウム塩誘導体を有効成分とする鎮痛薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050810

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: CHINA TAIWAN J MEDICINE CO., LTD.

Free format text: FORMER OWNER: JENKEN BIOSCIENCES INC.

Effective date: 20130902

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; TO: TAIWAN, CHINA

TR01 Transfer of patent right

Effective date of registration: 20130902

Address after: Taiwan, China

Patentee after: China Taiwan J Pharmaceutical Co.,Ltd.

Address before: The United States of North Carolina

Patentee before: JENKEN BIOSCIENCES, Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210323

Address after: Room 413, building 3, No. 1690, Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: Hengyi biomedical technology (Shanghai) Co.,Ltd.

Address before: Taiwan China

Patentee before: Taiwan J Pharmaceutical Co.,Ltd.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 201203 building 10, No. 860, Xinyang Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: Hengyi biomedicine (Shanghai) Co.,Ltd.

Address before: Room 413, building 3, 1690 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Patentee before: Hengyi biomedical technology (Shanghai) Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20130424

CX01 Expiry of patent term